Navigation Links
Cameron Associates Initiates Coverage of Brainsway, Ltd.

NEW YORK, Dec. 12, 2013 /PRNewswire/ -- Cameron Associates, Inc., a provider of investor relations services to public companies since 1976, today announced that it has initiated coverage of Brainsway Ltd. (TASE: BRIN), a medical technology company that leverages long-accepted transcranial magnetic stimulation (TMS) technology to pioneer a novel, non-invasive, cost effective and reimbursable therapy in an outpatient setting for a broad range of brain disorders.  An excerpt from the full 41 page Initiation Report follows below and is available to download at the Cameron Associates website at

Non-invasive, Clinically Effective Deep TMS Therapy for Depression is But a Start

  • Brainsway makes a case for innovative, yet conservative, clinical and cost effective treatment, as its non-invasive deep Transcranial Magnetic Stimulation (TMS) technology stimulates up to 6cm-7cm below the surface, reaching regions in the brain known to affect depression – in addition to multiple other central nervous system disorders – without surgical intervention.  FDA cleared for depression, deep TMS cost to the US healthcare system is an average reimbursement of $200 per session
  • Positive risk/benefit leverage to large market opportunity. US major depression disorder market alone for the 10%-20% of patients that are non-or-poor responders to drug therapy is estimated at $3Bn–$6Bn per year. Brainsway's depression clinical data trumps those of competing surface TMS, with response rate of 38.4% vs. 22.1% and remission rate of 32.6% vs. 9%, respectively
  • Broad deep TMS treatment applications.  CE Mark approved indications include Major Depression Disorder, smoking cessation, chronic neuropathic pain, post traumatic stress disorder, Parkinson's Disease, Alzheimer's Disease, schizophrenia–negative symptoms, autism, and bipolar disorder.  Others in evaluation include OCD and Blood Brain Barrier (BBB) permeability for potential entry into brain tumor drug delivery
  • Multiple indications support pay-per-use model, driving utilization and target industry-high margins.  Early in its US commercialization and with five announced exclusive international distribution partnerships, Brainsway is positioning for 25%+ revenue growth with potential 85% gross and 35% operating margins
  • A 1% penetration of the US depression market alone yields potential revenue of $130 million.  This translates to a price/revenue multiple of 1.1x without considering OUS and opportunities from over twenty other indications, including eight with CE Mark approvals
  • Technology licensed exclusively from the US National Institutes of Health for the life of the IP.  A next gen multi-channel stimulator is also poised to enter clinical evaluation

About Cameron Associates, Inc.

Cameron Associates, founded in 1976, provides strategic counsel to companies that need guidance in achieving key business goals, such as improved visibility and reputation in the equity markets, proper positioning of complex financial transactions, and communicating critical corporate issues. We have earned the respect of the Street and have built long-lasting relationships due to our ability to deliver consistently reliable and credible investor relations and capital markets advice to our clients.

For more information, please visit:

Important Disclosures:

The research report described in this press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell securities. The securities discussed in Cameron Associates research reports may be unsuitable for some investors depending on their specific investment objectives, financial status, risk profile, or particular needs. Investors should consider Cameron Associates reports as only a single factor in making their investment decisions and should not rely solely on these reports in evaluating whether or not to buy or sell the securities of the subject company. Cameron Associates has been compensated by the company that is the subject of the report described and future research reports and investor relations services. Please read the reports full disclosures on the Cameron Associates website,, before investing. Cameron Associates is not a registered investment adviser or broker-dealer.

Forward-Looking Statements

This press release contains forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those projected. These forward-looking statements represent Cameron Associates judgment as of the date of this release. Cameron Associates disclaims, however, any intent or obligation to update these forward-looking statements.

SOURCE Cameron Associates
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Closes Cameron Health Acquisition
2. LABSCO Acquires J & S Medical Associates
3. Accelera Innovations, Inc. Announces Stock Purchase Agreement With Behavioral Health Care Associates, Ltd.
4. Sutter Health and Radiological Associates of Sacramento Join Forces
5. Singh & Associates and Sughrue Mion PLLC in association with Lex WITNESS present The IPR Exchange - An Indo US IPR Summit
6. Link Between Cancer and Obesity Argues for More Aggressive Treatments, says Dr. Feiz & Associates
7. Positron Retains Investment Banking Firm Covington Associates To Lead Financing Of Cyclotron Project
8. Edgemont Capital Completes Sale Of Vince & Associates Clinical Research
9. J.D. Power and Associates Reports: Evidence that Relationship Marketing Still Matters in Oncology Pharmaceutical Sales
10. Managed Health Care Associates, Inc. (MHA) Released Results of Sixth Annual Independent Long Term Care Member Study with Expanded Specialty Pharmacy Findings
11. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
(Date:11/25/2015)... 2015  The total global healthcare industry is expected to ... Latin America has the highest projected growth ... Japan ), is second with growth projected at ... increased healthcare expenditure. In 2013-2014, total government funded healthcare was ... 2008-2009 to 41.2% in 2013-2014. In real terms, out of ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... 27th edition of USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, ... The digital component is distributed nationally, through a vast social media strategy and ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced today ... Group (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics SL ... users, partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing ...
(Date:11/27/2015)... ... 2015 , ... CBD College is proud to announce that on ... accreditation to its Diagnostic Medical Sonography program. CBD College is honored to join this ... colleges and universities in the state of California make the cut. CBD College is ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer ... incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product ... Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not only ...
(Date:11/26/2015)... ... November 26, 2015 , ... Somu Sivaramakrishnan announced today that ... Somu now offers travelers, value and care based Travel Services, including exclusive pricing ... well as, cabin upgrades and special amenities such as, shore excursions, discounted fares, ...
Breaking Medicine News(10 mins):